SEC Comment Letter for SYNLOGIC, INC. (SYBX) (CIK 0001527599) (SYBX) — Jun 30, 2017
SYNLOGIC, INC. (SYBX) (CIK 0001527599)
Date: June 30, 2017 · CIK: 0001527599 · Accession: 0000000000-17-023113
AI Filing Summary & Sentiment
Reasoning
Letter
June 30, 2017 Paul Lammers President & Chief Executive Officer Mirna Therapeutics, Inc. 1250 South Capital of Texas Highway Building 3, Suite 400 Austin, TX 78746 Mirna Therapeutics, Inc. Registration Statement on Form S-4 Filed June 21, 2017 File No. 333-218885Re: Dear Dr. Lammers: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jeffrey Gabor at (202) 551-2544 with any questions. Division of Corporation Finance Office of Healthcare & Insurance
Show Raw Text
June 30, 2017
Paul Lammers
President & Chief Executive Officer
Mirna Therapeutics, Inc.
1250 South Capital of Texas Highway
Building 3, Suite 400
Austin, TX 78746
Mirna Therapeutics, Inc.
Registration Statement on Form S-4
Filed June 21, 2017
File No. 333-218885Re:
Dear Dr. Lammers:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jeffrey Gabor at (202) 551-2544 with any questions.
Division of Corporation Finance
Office of Healthcare & Insurance